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See Article, pages 528–536Hepatitis C virus (HCV) eradication with interferon
(IFN)-ribavirin (RBV) combination therapy is the ther-
apeutic paradigm for patients with chronic hepatitis C.
Since the empirical choice to use interferon alfa in
1986, therapy for chronic hepatitis C has, in fact,
evolved substantially over the past two decades. In fact
the attainable sustained virological response (SVR) rates
have consistently increased over the years, the major
improvement in the treatment of HCV infection being
the addition of RBV to IFN-based therapy [1,2]. While
its mechanism of action still remains unclear, and even if
RBV monotherapy actually shows no antiviral eﬀect
in vitro, the combination of IFN and RBV gave SVR
rates of 30–35% in HCV genotype 1 patients and 75–
80% in HCV-2 and 3 patients, exceeding by far those
obtained with IFN monotherapy [3,4].
The latest change in anti-HCV treatment has been the
pegylation of the IFNmolecule, and pegylated IFN (Peg-
IFN) has become the standard of care for chronic hepati-
tis on account of its more potent acute antiviral eﬀect,
especially in HCV-1 patients, and also its ‘‘user-friendly”
once-a-week administration. Two forms of PegIFN exist
(a2a and a2b) which diﬀer signiﬁcantly in terms of phar-
macokinetics and dynamics, however, whether these
peculiarities translate into diﬀerent eﬃcacy rates is still
unknown, the latest data suggesting that SVR rates
obtained by the two compounds combined with RBV0168-8278/$34.00  2008 European Association for the Study of the Liver.
doi:10.1016/j.jhep.2008.07.003
Associate Editor: M. Colombo
q The author does not have a relationship with the manufacturers of
the drug involved, either in the past or in the present and did not
receive funding from the manufacturers to carry out this research.
* Tel.: +39 02 39014312; fax: +39 02 3546277.
E-mail address: garattini@marionegri.itare comparable in HCV-1 patients [5]. Preliminary evi-
dence is gathering that both types of PegIFN can be alter-
natively used as standard of care in naı¨ve HCV patients
[6,7], butwe ignore the percentage of infectedpatients that
ultimately do receive PegIFN/RBV therapy.
Lettmeier et al. in the paper which appears in this issue
of the Journal, present a careful analysis concerning the
sales of PegIFN a2a and 2b in 21 countries for the treat-
ment of chronic hepatitis induced byHCV [8]. These data
were then utilized to estimate the number of patients trea-
ted and to conclude that the access to PegIFNs may diﬀer
considerably in the various countries. The authors have
themerit of translating sales into number of patients trea-
ted by developing for the ﬁrst time an algorithm that takes
account of genotype distribution, patient characteristics
and practice patterns. For reasons of simpliﬁcation,
instead of reporting the sales ﬁgures for single countries
they have preferred to group them into four categories:
EU foundermembers, countries that joined theEUbefore
2000, after 2000 and non-EU states. It is hard to see the
rationale for this grouping. For a more rational compar-
ison of the results, it would have been better to analyze
sales in relation to the prevalence of HCV cases in the sin-
gle countries. It is in fact reasonable to suppose that com-
parisons of access to therapy are more meaningful in
relation to the dimensions of the infection in the various
countries: the problem is diﬀerent in the Czech Republic,
the Netherlands and Sweden where the prevalence of
HCV ranges between 0.2% and 0.5% while in Spain, Italy
and Romania the range is 1.5–4.5%.
An important omission in this paper is data concern-
ing the utilization of standard IFNs because in some
countries low access to PegIFNs may possibly be coun-
terbalanced by the sales of standard IFNs. The authors
seem to overlook this aspect because they state in thePublished by Elsevier B.V. All rights reserved.
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(are) the state-of-the art drugs for treatment of chronic
hepatitis”. This statement can be challenged because,
although this is the current opinion, it must be stressed
that there is virtually a vacuum of randomized clinical
trials comparing either the two PegIFNs now on the
market, or the single PegIFNs with the corresponding
standard IFN. The studies available are biased by their
low numbers, lack of blinding and the authorship and
sponsorship of the companies producing PegIFNs. Fur-
thermore, there seems to be no agreement about the
doses: the weekly dose of PegIFN a2a may range from
1.5 lg/kg [9] to 2.5 lg/kg, this latter extrapolated from
a dose of 180 lg for an average person weighing 70 kg.
[10,11] similarly to PegIFN a2b [12,13]. The dose of
the standard IFNs can also be 3 M I.U. twice [12] or
three times [14,15] a week. In some cases, IFN a2a has
been used at the dose of 6 M I.U. three times a week
for 12 weeks followed by 3 M I.U. [10]. It is clear that
since no dose ranging has been done, no comparison
can be made at optimal doses for the two classes of
IFNs. In addition, it would be important to establish
how much RBV has been sold and utilized, to check
whether in many cases PegIFNs were used alone.
Another point not adequately discussed is whether
PegIFNs induce more adverse eﬀects than standard
IFNs [12,16,17] such as neutropenia, thrombocytopenia,
arthralgia and injection-site reactions.
The authors explain the diﬀerent access to PegIFNs
by considering in particular that reduced access to
therapy was common in low-resource countries. This
may not be the only reason if the Czech Republic
treats about 11% of prevalent cases with PegIFNs
while Belgium, Italy, UK and Denmark use them
for less than 4%. Important diﬀerences exist between
the use of the a2a and 2b PegIFNs: for instance in
Switzerland a2a largely predominates while in France
the winner is a2b. This is probably explained by the
task force of detailmen of the producers in the various
countries.
Previous studies about the access to treatment with
IFNs and RBV – without distinctions among the type
of IFN utilized – have shown that US patients were less
likely to receive treatment if they were older, single, ane-
mic, with hepatic dysfunctions, had HCV genotype 1
and if they were evaluated by less experienced providers
[18].
In Canada, where PegIFNs and IFNs are similarly
priced, a technology report from the Canadian Agency
for Drugs and Technologies in Health [16] is particularly
interesting. On the basis of the literature, it concluded
that PegIFNs and RBV attain a higher overall sustained
virological response rate, particularly for genotypes 2
and 3, than standard IFNs and RBV. However it is
not known whether this will translate into real advanta-
ges in the natural history of chronic hepatitis which fre-quently develops in an unpredictable way over decades.
For the moment, the report states that the two treat-
ments do not present detectable diﬀerences in all-cause
mortality or withdrawals due to adverse eﬀects although
the treatment of PegIFNs and RBV is associated with a
signiﬁcantly higher rate of non-fatal serious adverse
eﬀects than the standard combination.
Clearly Lettmeier et al. [8] have opened the way to
discussing HCV patients’ access to therapy in diﬀerent
countries but establishing the best therapy in terms of
beneﬁt-risk in relation to cost still requires a lot of inde-
pendent clinical research.
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